Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference
-
Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference
-
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference
-
Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference
-
Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference
-
Zynerba Pharmaceuticals to Present at Two Upcoming Conferences
-
Canaccord Genuity Transfers Coverage on Zynerba Pharmaceuticals (ZYNE) at Buy
-
Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference
-
Zynerba Pharmaceuticals (ZYNE) PT Raised to $18 at Canaccord Genuity
-
UPDATE: Zynerba Pharmaceuticals (ZYNE) PT Raised to $15 at Canaccord Genuity
-
Zynerba Pharmaceuticals to Present at Canaccord Genuity’s 36th Annual Growth Conference
-
Canaccord Genuity Reiterates Buy on Zynerba Pharma (ZYNE) Following GW Pharmaceutical's (GWPH) Positive CBD Data
-
Canaccord Genuity Starts Zynerba Pharmaceuticals (ZYNE) at Buy
-
Zynerba Pharmaceuticals Announces Closing of Its Initial Public Offering and Exercise in Full of Option to Purchase Additional Shares
-
Zynerba Pharmaceuticals Announces Closing of Its Initial Public Offering and Exercise in Full of Option to Purchase Additional Shares
-
Zynerba Pharmaceuticals (ZYNE) IPO Opens Up 29% Higher
-
Zynerba Pharmaceuticals (ZYNE) Prices 3M Common Stock IPO at $14/Share
-
Zynerba Pharmaceuticals Announces Pricing of Its Initial Public Offering
-
Zynerba Pharmaceuticals Announces Pricing of Its Initial Public Offering
-
Zynerba Pharmaceuticals (ZYNE) Files $57.5M Common Stock IPO